Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study
Caladrius Biosciences Inc (NASDAQ:CLBS) suspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction (CMD). As previously communicated, the pandemic impacted the enrollment in the FREEDOM Trial coupled with supply chain issues making enrollment much slower and challenging to accelerate. The FREEDOM trial enrolled approximately one-third of the…
Benzinga ·
Benzinga
